# 03B LRRK2 KINASE Research Report **Protein:** 03B LRRK2 KINASE **Variant:** G2019S **UniProt ID:** Q5S007 **Disease Association:** Parkinson's disease **Report Generated:** 2026-07-14 01:46 UTC **AlphaFold Confidence (pLDDT):** 90.6% **Structure Folded:** 2026-07-05 --- ## Structure Summary LRRK2 is a large enzyme that regulates cellular processes, and mutations in LRRK2 are the most common genetic cause of Parkinson's disease. We analyzed the G2019S variant (a change from glycine to serine at position 2019) in the kinase domain, which showed excellent structural prediction quality with an average confidence score of 90.6. This variant is relatively common in the population (found in approximately 1 in 2,400 chromosomes) and is known to increase the enzyme's activity, contributing to neuronal dysfunction in Parkinson's disease. --- LRRK2 (leucine-rich repeat kinase 2) is a large, multi-domain protein kinase that plays critical roles in cellular functions including autophagy, vesicle trafficking, and mitochondrial quality control. Mutations in LRRK2 represent the most common known genetic cause of Parkinson's disease, accounting for 1-2% of all cases and up to 40% in certain populations. The G2019S variant analyzed here is located in the kinase domain, the catalytic core of the protein responsible for transferring phosphate groups to target proteins. The structural model of the LRRK2 kinase domain containing the G2019S variant was generated using computational prediction methods (AlphaFold2/ColabFold). The prediction achieved an average confidence score (pLDDT) of 90.6, indicating very high confidence in the predicted structure. This high confidence score suggests that the model accurately represents the three-dimensional arrangement of amino acids in this domain, providing a reliable foundation for understanding how the mutation affects protein structure. The G2019S mutation replaces a small, flexible glycine amino acid with a larger serine that contains a hydroxyl group. This substitution occurs in the activation segment of the kinase domain, a region that controls the enzyme's catalytic activity. Extensive biochemical studies have demonstrated that G2019S increases LRRK2's kinase activity approximately 2-3 fold compared to the normal protein, leading to excessive phosphorylation of downstream targets such as Rab GTPases. This hyperactivation is thought to disrupt normal cellular processes, particularly affecting dopamine-producing neurons that degenerate in Parkinson's disease. The population frequency data reveals that G2019S is found in approximately 0.042% of chromosomes (609 out of 1,461,622), making it relatively common for a disease-associated variant. While not currently listed in the ClinVar database with a formal pathogenicity classification, G2019S is well-established in the scientific literature as a pathogenic mutation with incomplete penetrance—meaning that not all carriers will develop Parkinson's disease. The age-dependent penetrance is estimated at 25-40% by age 60, increasing to 70-80% by age 80, indicating that genetic background and environmental factors also influence disease development. The prevalence of this variant varies significantly across populations, being particularly enriched in individuals of North African Berber and Ashkenazi Jewish ancestry. ## Similar Research **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase.** Fiesel et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40624741/) **Synergism of IP3R and Parkin mutants identifies mitochondrial stress as an early feature of Parkinson's disease.** Dileep et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41235839/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease.** Menozzi et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41569009/) --- ## AI Research Brief # Research Brief: LRRK2 G2019S Kinase Variant ## Pathogenic Mechanisms The LRRK2 G2019S variant represents a critical gain-of-function mutation affecting the kinase domain of leucine-rich repeat kinase 2, resulting in hyperactivated enzymatic activity. This mutation disrupts normal protein function across multiple molecular pathways, including ATP binding, actin binding, and beta-catenin destruction complex interactions. The hyperactive kinase leads to excessive phosphorylation of downstream Rab GTPases, particularly affecting Rab protein homeostasis and membrane trafficking. Functional consequences cascade through multiple biological processes including autophagy dysregulation, altered calcium-mediated signaling, and perturbation of the canonical Wnt signaling pathway. The variant induces both cell-autonomous striatal pathology and systemic neuroinflammatory responses, with particular impact on dopaminergic neuronal function. Key protein-protein interactions with YWHAG, MSN, SQSTM1, DNM1L, and RAB29 are compromised, contributing to disrupted membrane lipid homeostasis and cellular quality control mechanisms. The molecular architecture changes likely propagate through the protein's known interactome, amplifying pathogenic effects beyond direct kinase activity. ## Clinical Significance LRRK2 G2019S represents one of the most clinically significant and penetrant genetic risk factors for Parkinson's disease, though clinical presentation demonstrates important variability across different ancestral populations. This observation suggests complex gene-environment interactions and potential modifier effects that influence disease manifestation. The mutation's high penetrance yet variable expressivity highlights the importance of considering genetic background in risk assessment and therapeutic planning. The pathogenic classification of this variant as a major causative mutation in familial and sporadic Parkinson's disease makes it a priority target for precision medicine approaches. Clinical manifestations reflect the multisystem nature of LRRK2 dysfunction, encompassing motor symptoms related to dopaminergic deficits as well as non-motor features potentially linked to immune dysfunction and systemic inflammation. ## Therapeutic Landscape The LRRK2 G2019S variant presents compelling therapeutic opportunities through multiple modalities. Structural analysis identifies an aggregation-prone region at residues 64-68 (aggregation score: 0.78), suggesting potential for aggregation-modulating interventions. The hyperactive kinase phenotype makes this variant particularly amenable to small-molecule kinase inhibitor strategies, with ongoing development of LRRK2-selective inhibitors showing promise in preclinical models. Therapeutic strategies should focus on normalizing kinase activity rather than complete inhibition, given LRRK2's physiological roles in immune function and cellular homeostasis. The identified protein interactions provide additional therapeutic nodes, particularly targeting Rab protein phosphorylation pathways or modulating interactions with SQSTM1 to restore autophagy function. The aggregation hotspot near the N-terminus may represent a distinct therapeutic vulnerability separate from kinase inhibition approaches. ## Research Directions Critical knowledge gaps remain regarding genotype-phenotype correlations across diverse populations and the molecular basis for variable penetrance. Priority research areas include: (1) elucidating ancestry-specific modifiers that influence G2019S pathogenicity to enable personalized risk stratification; (2) characterizing the temporal dynamics of Rab phosphorylation and downstream pathway dysregulation to identify optimal therapeutic windows; (3) investigating the interplay between neuronal and immune cell dysfunction to determine whether peripheral biomarkers can track CNS pathology; (4) developing structural insights into how G2019S alters kinase domain conformation and substrate specificity; and (5) exploring combination approaches targeting both kinase hyperactivity and protein aggregation. Longitudinal studies in mutation carriers are essential for understanding prodromal disease phases and identifying preventive intervention opportunities. --- ## Agent Findings ### Literature (1) - **2026-07-05:** These papers are highly relevant to understanding LRRK2 G2019S pathogenic mechanisms and clinical implications in PD. They reveal critical ethnic variations in G2019S prevalence, elucidate molecular pathways linking LRRK2 kinase activity to GCase regulation and Rab8a phosphorylation, identify CSF LRRK2 as a progression biomarker, and demonstrate that LRRK2 variants do not significantly alter DBS treatment responses. Collectively, they advance precision medicine approaches for LRRK2-associated PD through mechanistic insights and clinical biomarker development. ### Clinical (1) - **2026-07-05:** ### Structural (1) - **2026-07-06:** AlphaFold structure update: Baseline check: 1 structure(s) found ### Synthesis (1) - **2026-07-06:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The LRRK2 G2019S variant represents one of the most clinically actionable targets in Parkinson's dis... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)